Prestige BioPharma Pte Ltd.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Prestige BioPharma Pte Ltd.
The vice-chairman of Singapore-based Prestige Group talks to Scrip about the biopharma's strategies in Asia and elsewhere, as it focuses on vaccines for COVID-19 and other diseases, along with novel antibody therapeutics in oncology and biosimilars.
As Prestige BioPharma announced plans for Phase I and Phase III trials of its PBP1502 proposed adalimumab biosimilar, as well as expected filing dates in the EU and US, the company outlined how it believes its proprietary technology will allow its Humira rival to compete aggressively on price.
Saudi firm Tabuk has struck a deal to sell Prestige BioPharma’s Tuznue trastuzumab biosimilar in the MENA region.
German biotech could realize more than $2bn in earnouts under pact with Roivant. Galmed teams with MyBiotics in attempt to optimize clinical response to its Phase III NASH candidate Aramchol.
- Large Molecule
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.